In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...

In fact, AbbVie reported a $4.6 billion loss in ... That pattern was attenuated by the success of its Covid-19 vaccine, which Pfizer produced in the United States for the United States and many ...

Medical-device maker Stryker on Monday agreed to acquire Inari Medical , which makes devices that treat patients with venous ...

That said, noted vaccine skeptic Robert F ... Pfizer—which has taken flak for failing to make good on its immense COVID-19 profits—is expected to slip in the rankings of top drugmakers ...

BioNTech, which became a household name when it partnered with Pfizer to develop a Covid-19 vaccine, is now making ... according to Jefferies. AbbVie’s experimental drug Rinvoq to treat in ...

Editor’s Note: The Business Journal this week is honoring Gavin Herbert with our first ever Lifetime Achievement Recognition.

General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

No scientific studies have established a causal relationship between the Pfizer vaccine and conditions that cause the excessive growth of breasts.

BARDA tapped a team of Fred Hutch Cancer Center biostatisticians to determine the biomarkers that will serve as predictors of ...